Does the media favor YARW or IMRX?

In the previous week, Yarrow Bioscience had 7 more articles in the media than Immuneering. MarketBeat recorded 14 mentions for Yarrow Bioscience and 7 mentions for Immuneering. Yarrow Bioscience's average media sentiment score of 0.58 beat Immuneering's score of -0.09 indicating that Yarrow Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media prefer YARW or EBS?

In the previous week, Yarrow Bioscience had 7 more articles in the media than Emergent Biosolutions. MarketBeat recorded 14 mentions for Yarrow Bioscience and 7 mentions for Emergent Biosolutions. Yarrow Bioscience's average media sentiment score of 0.58 beat Emergent Biosolutions' score of 0.48 indicating that Yarrow Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent Biosolutions 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MYGN or YARW?

In the previous week, Yarrow Bioscience had 6 more articles in the media than Myriad Genetics. MarketBeat recorded 14 mentions for Yarrow Bioscience and 8 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.64 beat Yarrow Bioscience's score of 0.58 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Yarrow Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GALT or YARW?

In the previous week, Yarrow Bioscience had 10 more articles in the media than Galectin Therapeutics. MarketBeat recorded 14 mentions for Yarrow Bioscience and 4 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.80 beat Yarrow Bioscience's score of 0.58 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Yarrow Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BCYC or YARW?

In the previous week, Yarrow Bioscience had 12 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 14 mentions for Yarrow Bioscience and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.94 beat Yarrow Bioscience's score of 0.58 indicating that Bicycle Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Yarrow Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Yarrow Bioscience (YARW) Competitors

$26.26 -0.75 (-2.78%)

Closing price 04:00 PM Eastern

Extended Trading

$26.87 +0.61 (+2.31%)

As of 07:30 PM Eastern

Compare

YARW vs. IMRX, EBS, MYGN, GALT, and BCYC

Should you buy Yarrow Bioscience stock or one of its competitors? Yarrow Bioscience's main competitors and comparable companies include Immuneering (IMRX), Emergent Biosolutions (EBS), Myriad Genetics (MYGN), Galectin Therapeutics (GALT), and Bicycle Therapeutics (BCYC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Yarrow Bioscience compare to Immuneering?

Yarrow Bioscience (NASDAQ:YARW) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Yarrow Bioscience had 7 more articles in the media than Immuneering. MarketBeat recorded 14 mentions for Yarrow Bioscience and 7 mentions for Immuneering. Yarrow Bioscience's average media sentiment score of 0.58 beat Immuneering's score of -0.09 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral

Yarrow Bioscience has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 14.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Yarrow Bioscience currently has a consensus price target of $58.00, suggesting a potential upside of 120.87%. Immuneering has a consensus price target of $17.50, suggesting a potential upside of 304.16%. Given Immuneering's stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Immuneering has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Immuneering's return on equity of -27.15% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Immuneering	N/A	-27.15%	-25.75%

Yarrow Bioscience has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	123.01	-$26.48M	-$14.64	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

Summary

Immuneering beats Yarrow Bioscience on 9 of the 16 factors compared between the two stocks.

How does Yarrow Bioscience compare to Emergent Biosolutions?

Yarrow Bioscience (NASDAQ:YARW) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Yarrow Bioscience currently has a consensus target price of $58.00, suggesting a potential upside of 120.87%. Emergent Biosolutions has a consensus target price of $10.00, suggesting a potential upside of 57.33%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, research analysts clearly believe Yarrow Bioscience is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Yarrow Bioscience had 7 more articles in the media than Emergent Biosolutions. MarketBeat recorded 14 mentions for Yarrow Bioscience and 7 mentions for Emergent Biosolutions. Yarrow Bioscience's average media sentiment score of 0.58 beat Emergent Biosolutions' score of 0.48 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Emergent Biosolutions has a net margin of -22.95% compared to Yarrow Bioscience's net margin of -4,726.21%. Emergent Biosolutions' return on equity of 16.35% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Emergent Biosolutions	-22.95%	16.35%	6.17%

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Emergent Biosolutions has higher revenue and earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	123.01	-$26.48M	-$14.64	N/A
Emergent Biosolutions	$742.90M	0.44	$52.60M	-$3.55	N/A

Yarrow Bioscience has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market.

Summary

Emergent Biosolutions beats Yarrow Bioscience on 10 of the 16 factors compared between the two stocks.

How does Yarrow Bioscience compare to Myriad Genetics?

Myriad Genetics (NASDAQ:MYGN) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Myriad Genetics has a net margin of -13.96% compared to Yarrow Bioscience's net margin of -4,726.21%. Myriad Genetics' return on equity of -16.09% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Yarrow Bioscience has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.44	-$365.90M	-$1.19	N/A
Yarrow Bioscience	$570K	123.01	-$26.48M	-$14.64	N/A

Myriad Genetics currently has a consensus price target of $3.12, suggesting a potential downside of 17.68%. Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 120.87%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Yarrow Bioscience is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Yarrow Bioscience had 6 more articles in the media than Myriad Genetics. MarketBeat recorded 14 mentions for Yarrow Bioscience and 8 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.64 beat Yarrow Bioscience's score of 0.58 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Yarrow Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Myriad Genetics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market.

Summary

Yarrow Bioscience beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.

How does Yarrow Bioscience compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Yarrow Bioscience had 10 more articles in the media than Galectin Therapeutics. MarketBeat recorded 14 mentions for Yarrow Bioscience and 4 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.80 beat Yarrow Bioscience's score of 0.58 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Yarrow Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 186.46%. Yarrow Bioscience has a consensus target price of $58.00, suggesting a potential upside of 120.87%. Given Galectin Therapeutics' higher possible upside, equities research analysts plainly believe Galectin Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Yarrow Bioscience has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Yarrow Bioscience	$570K	123.01	-$26.48M	-$14.64	N/A

Galectin Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Galectin Therapeutics' return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Galectin Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market.

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Yarrow Bioscience beats Galectin Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Yarrow Bioscience compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Yarrow Bioscience has lower revenue, but higher earnings than Bicycle Therapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.74	-$218.96M	-$2.73	N/A
Yarrow Bioscience	$570K	123.01	-$26.48M	-$14.64	N/A

Bicycle Therapeutics has a net margin of -311.11% compared to Yarrow Bioscience's net margin of -4,726.21%. Bicycle Therapeutics' return on equity of -33.22% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Bicycle Therapeutics currently has a consensus price target of $13.86, suggesting a potential upside of 256.22%. Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 120.87%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Bicycle Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bicycle Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market.

In the previous week, Yarrow Bioscience had 12 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 14 mentions for Yarrow Bioscience and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.94 beat Yarrow Bioscience's score of 0.58 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Yarrow Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bicycle Therapeutics beats Yarrow Bioscience on 12 of the 16 factors compared between the two stocks.

Get Yarrow Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YARW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YARW vs. The Competition

Export

Metric	Yarrow Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$72.11M	$3.86B	$7.15B	$13.98B
Dividend Yield	N/A	3.66%	2.57%	11.70%
P/E Ratio	-1.79	14.33	272.99	25.37
Price / Sales	123.01	1,295.87	602.82	70.35
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.63	15.26	10.43	6.24
Net Income	-$26.48M	-$22.78M	$3.49B	$358.08M
7 Day Performance	-13.08%	-2.03%	-2.11%	-1.43%
1 Month Performance	-38.20%	2.10%	0.64%	-2.71%
1 Year Performance	N/A	42.58%	24.61%	8.46%

Yarrow Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YARW Yarrow Bioscience	2.5202 of 5 stars	$26.26 -2.8%	$58.00 +120.9%	N/A	$72.11M	$570K	N/A	30	News Coverage Short Interest Increase
IMRX Immuneering	2.727 of 5 stars	$4.78 -0.8%	$17.50 +266.1%	-49.7%	$309.25M	N/A	N/A	60
EBS Emergent Biosolutions	4.3523 of 5 stars	$6.01 -3.3%	$10.00 +66.5%	-23.2%	$307.64M	$742.30M	N/A	2,420
MYGN Myriad Genetics	1.0859 of 5 stars	$3.18 -0.3%	$3.60 +13.2%	-52.8%	$304.17M	$806.60M	N/A	2,700
GALT Galectin Therapeutics	1.9627 of 5 stars	$4.14 -10.2%	$11.00 +165.7%	-27.2%	$303.60M	N/A	N/A	9	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:YARW) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Yarrow Bioscience (YARW) Competitors

YARW vs. IMRX, EBS, MYGN, GALT, and BCYC

How does Yarrow Bioscience compare to Immuneering?

Summary

How does Yarrow Bioscience compare to Emergent Biosolutions?

Summary

How does Yarrow Bioscience compare to Myriad Genetics?

Summary

How does Yarrow Bioscience compare to Galectin Therapeutics?

Summary

How does Yarrow Bioscience compare to Bicycle Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW vs. The Competition

Yarrow Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Yarrow Bioscience (YARW) Competitors

YARW vs. IMRX, EBS, MYGN, GALT, and BCYC

How does Yarrow Bioscience compare to Immuneering?

Does the media favor YARW or IMRX?

Which has more risk and volatility, YARW or IMRX?

Do insiders & institutionals believe in YARW or IMRX?

Do analysts rate YARW or IMRX?

Is YARW or IMRX more profitable?

Which has stronger valuation and earnings, YARW or IMRX?

Summary

How does Yarrow Bioscience compare to Emergent Biosolutions?

Do analysts prefer YARW or EBS?

Does the media prefer YARW or EBS?

Is YARW or EBS more profitable?

Do insiders and institutionals hold more shares of YARW or EBS?

Which has stronger earnings and valuation, YARW or EBS?

Which has more risk and volatility, YARW or EBS?

Summary

How does Yarrow Bioscience compare to Myriad Genetics?

Is MYGN or YARW more profitable?

Which has higher earnings and valuation, MYGN or YARW?

Do analysts rate MYGN or YARW?

Do institutionals & insiders believe in MYGN or YARW?

Does the media favor MYGN or YARW?

Which has more volatility & risk, MYGN or YARW?

Summary

How does Yarrow Bioscience compare to Galectin Therapeutics?

Does the media favor GALT or YARW?

Do analysts rate GALT or YARW?

Which has preferable valuation and earnings, GALT or YARW?

Is GALT or YARW more profitable?

Which has more risk and volatility, GALT or YARW?

Do insiders & institutionals believe in GALT or YARW?

Summary

How does Yarrow Bioscience compare to Bicycle Therapeutics?

Which has stronger earnings & valuation, BCYC or YARW?

Is BCYC or YARW more profitable?

Do analysts recommend BCYC or YARW?

Do insiders and institutionals believe in BCYC or YARW?

Which has more risk & volatility, BCYC or YARW?

Does the media refer more to BCYC or YARW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW vs. The Competition

Yarrow Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools